KMT2A and acute myeloid leukemia: Considering that AMLs with KMT2Ar, NUP98r, and NPM1 have been shown to be dependent on KMT2A/Menin96–98, and that a Menin inhibitor (SNDX-5613) targeting KMT2Ar and NPM1 AML is in a clinical trial99 (NCT04065399), our data suggest that other subtypes marked by HOX expression, such as UBTF or DEK::NUP214, may also be candidates for Menin inhibitors.